CA3243418A1 - COMPOUNDS AND RADIOLIGANDS TO TARGET THE NEUROTENSIN RECEPTOR AND RELATED USES - Google Patents

COMPOUNDS AND RADIOLIGANDS TO TARGET THE NEUROTENSIN RECEPTOR AND RELATED USES

Info

Publication number
CA3243418A1
CA3243418A1 CA3243418A CA3243418A CA3243418A1 CA 3243418 A1 CA3243418 A1 CA 3243418A1 CA 3243418 A CA3243418 A CA 3243418A CA 3243418 A CA3243418 A CA 3243418A CA 3243418 A1 CA3243418 A1 CA 3243418A1
Authority
CA
Canada
Prior art keywords
compound
groups
solvate
pharmaceutically acceptable
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3243418A
Other languages
English (en)
French (fr)
Inventor
Fa Liu
Original Assignee
Full Life Technologies Hk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Full Life Technologies Hk Ltd filed Critical Full Life Technologies Hk Ltd
Publication of CA3243418A1 publication Critical patent/CA3243418A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3243418A 2022-02-18 2023-02-17 COMPOUNDS AND RADIOLIGANDS TO TARGET THE NEUROTENSIN RECEPTOR AND RELATED USES Pending CA3243418A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263311621P 2022-02-18 2022-02-18
US63/311,621 2022-02-18
PCT/US2023/013314 WO2023158802A1 (en) 2022-02-18 2023-02-17 Compounds and radioligands for targeting neurotensin receptor and uses thereof

Publications (1)

Publication Number Publication Date
CA3243418A1 true CA3243418A1 (en) 2023-08-24

Family

ID=87579080

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3243418A Pending CA3243418A1 (en) 2022-02-18 2023-02-17 COMPOUNDS AND RADIOLIGANDS TO TARGET THE NEUROTENSIN RECEPTOR AND RELATED USES

Country Status (11)

Country Link
US (2) US12145926B2 (https=)
EP (1) EP4479040A1 (https=)
JP (1) JP2025506705A (https=)
KR (1) KR20240150464A (https=)
CN (1) CN119136796A (https=)
AU (1) AU2023221977A1 (https=)
CA (1) CA3243418A1 (https=)
CL (1) CL2024002422A1 (https=)
IL (1) IL314786A (https=)
MX (1) MX2024009858A (https=)
WO (1) WO2023158802A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4479040A1 (en) 2022-02-18 2024-12-25 Full-Life Technologies HK Limited Compounds and radioligands for targeting neurotensin receptor and uses thereof
WO2025146126A1 (en) * 2024-01-04 2025-07-10 Full-Life Technologies Hk Limited Preparation method of compounds targeting neurotensin receptor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
DE4307983A1 (de) 1993-03-13 1994-09-15 Beiersdorf Ag Wirkstoffe und kosmetische und dermatologische Zubereitungen
FR2732967B1 (fr) * 1995-04-11 1997-07-04 Sanofi Sa 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
EP2740726A1 (en) * 2012-12-07 2014-06-11 3B Pharmaceuticals GmbH Neurotensin receptor ligands
RU2743781C2 (ru) 2014-06-10 2021-02-25 3Б Фармасьютикалз Гмбх Конъюгат, содержащий лиганд рецепторов нейротензина, и его применение
EP3279197A1 (en) 2016-08-03 2018-02-07 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnosis, treatment and prevention of neurotensin receptor-related conditions
EP4479040A1 (en) 2022-02-18 2024-12-25 Full-Life Technologies HK Limited Compounds and radioligands for targeting neurotensin receptor and uses thereof

Also Published As

Publication number Publication date
JP2025506705A (ja) 2025-03-13
EP4479040A1 (en) 2024-12-25
US12145926B2 (en) 2024-11-19
US20240287046A1 (en) 2024-08-29
WO2023158802A1 (en) 2023-08-24
CN119136796A (zh) 2024-12-13
US20250026739A1 (en) 2025-01-23
AU2023221977A1 (en) 2024-08-15
IL314786A (en) 2024-10-01
KR20240150464A (ko) 2024-10-15
CL2024002422A1 (es) 2024-12-06
MX2024009858A (es) 2024-11-08

Similar Documents

Publication Publication Date Title
ES2910941T3 (es) Ligandos de proteína de activación de fibroblastos para aplicaciones de administración dirigida
JP7515023B2 (ja) 二重標的化化合物及びその調製方法と応用
ES2615805T3 (es) Conjugados de antagonista de péptido análogo de la bombesina
AU2022219525B2 (en) Bivalent fibroblast activation protein ligands for targeted delivery applications
KR20230165818A (ko) 섬유아세포 활성화 단백질 알파 및/또는 전립선-특이적 막 항원을 표적화하는 이종이가 및 동형이가 제제
EP4436979A1 (en) Cleavable radioligands for targeting cell surface receptors and uses thereof
US20250026739A1 (en) Compounds and radioligands for targeting neurotensin receptor and uses thereof
BR112019023246B1 (pt) Compostos compreendendo uma fração quelante, métodos para produção dos mesmos e usos dos mesmos
ES2899860T3 (es) Nuevo compuesto que contiene nitrógeno o sal del mismo, o complejo de metal de los mismos
WO2020009093A1 (ja) Ｃｘｃｒ４結合性化合物もしくはその塩またはそれらと金属との錯体
ES2985919T3 (es) Agentes diagnósticos y terapéuticos dirigidos a CXCR4 con selectividad de especie reducida
WO2024063648A1 (en) Platform and scaffold for FAP targeting agents
IL296081A (en) Cyclic peptides and their conjugates for addressing alpha-v-beta-6 integrin in vivo
TW202409009A (zh) 黑素皮質素2型受體(mc2r)之靶向治療劑及其用途
HK40114422A (zh) 靶向神经降压素受体的化合物和放射性配体及其用途
WO2024083224A1 (en) Dual receptor targeting radioligands and uses thereof related applications
JP2025532147A (ja) Ｆａｐ標的化剤のプラットフォーム及び足場
BR112023015831B1 (pt) Ligantes de proteína de ativação de fibroblastos bivalentes para aplicações de liberação direcionada, composições farmacêuticas, seus usos e métodos para preparar um conjugado
TW202428306A (zh) 神經肽y1受體(npy1r)靶向治療劑及其用途
WO2025088200A2 (en) Acid phosphatase 3 ligands for targeted delivery applications
AU2024365851A1 (en) Acid phosphatase 3 ligands for targeted delivery applications

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240726

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20240729

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240729

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240729

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241001

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250108

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250108

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250108

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260211

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260212